A Study of AIP-303 in HER2 Positive Breast Cancer and/or Metastatic Breast Cancer Patients
Status:
Not yet recruiting
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
The HEROINE-Breast01 study is a Phase I/II clinical study of a new investigational agent,
AIP-303 to help patients with metastatic or unresectable HER2-positive breast cancer and for
women with previously treated HER2 positive breast cancer who have gone through at least two
prior lines of treatment and received other HER-2-targeted drugs, Trastuzumab or
Ado-Trastuzumab and chemotherapy as part of earlier treatments and who have progressed on one
or more available therapies. AIP-303 may help slow down tumor growth and this might improve
outcomes and quality-of-life for these patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Advanced Imaging Projects, LLC
Collaborators:
All India Institute of Medical Sciences, New Delhi PositronPharma Postgraduate Institute of Medical and Research Università degli studi di Trieste University of Lausanne University of Witwatersrand, South Africa US Department of Veterans Affairs